Equities researchers at Lake Street Capital began coverage on shares of Assertio (NASDAQ:ASRT – Get Rating) in a note issued to investors on Monday, Marketbeat Ratings reports. The firm set a "buy" rating and a $7.00 price target on the stock. Lake Street Capital's target price points to a potential upside of 167.18% from the company's previous close.
A number of other brokerages have also commented on ASRT. TheStreet raised shares of Assertio from a "d" rating to a "c-" rating in a research report on Wednesday, August 3rd. StockNews.com lowered Assertio from a "buy" rating to a "hold" rating in a research report on Monday, October 31st. Finally, Roth Capital restated a "buy" rating on shares of Assertio in a research note on Wednesday, August 24th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $7.00.
Get Assertio alerts:Assertio Price Performance
ASRT opened at $2.62 on Monday. The business has a fifty day moving average of $2.39 and a 200 day moving average of $2.79. The stock has a market cap of $126.23 million, a P/E ratio of 4.85, a PEG ratio of 0.53 and a beta of 1.66. The company has a quick ratio of 0.90, a current ratio of 1.00 and a debt-to-equity ratio of 0.39. Assertio has a 52-week low of $1.19 and a 52-week high of $4.44.
Assertio (NASDAQ:ASRT – Get Rating) last issued its earnings results on Monday, August 8th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. The firm had revenue of $35.13 million during the quarter, compared to analyst estimates of $31.62 million. Assertio had a net margin of 19.35% and a return on equity of 22.98%. During the same period in the previous year, the firm earned ($0.32) earnings per share. As a group, sell-side analysts anticipate that Assertio will post 0.51 EPS for the current year.Institutional Trading of Assertio
Several hedge funds and other institutional investors have recently bought and sold shares of ASRT. Russell Investments Group Ltd. bought a new stake in Assertio during the second quarter valued at about $28,000. Sigma Planning Corp bought a new stake in shares of Assertio in the 2nd quarter valued at about $32,000. Virtu Financial LLC purchased a new position in shares of Assertio in the 3rd quarter worth approximately $37,000. Advisor Group Holdings Inc. lifted its position in Assertio by 2,983.7% during the first quarter. Advisor Group Holdings Inc. now owns 13,229 shares of the company's stock valued at $38,000 after acquiring an additional 12,800 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new stake in Assertio during the second quarter valued at approximately $40,000. Institutional investors own 27.93% of the company's stock.
Assertio Company Profile
(Get Rating)
Assertio Holdings, Inc, a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
Recommended Stories
- Get a free copy of the StockNews.com research report on Assertio (ASRT)
- The Cheesecake Factory Shows You Can Have It and Eat It Too
- Two EV Stocks That Could Rally Into Year-End
- 3 High Yields The Institutions Are Buying
- Can Activision Blizzard Rally Into Year End?
- Despite Financials, Twiliio is One To Watch
Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with MarketBeat.com's FREE daily email newsletter.